Skip to main content
Top
Published in: Inflammation 6/2010

01-12-2010

Increased Extracellular Survivin in the Synovial Fluid of Rheumatoid Arthritis Patients: Fibroblast-like Synoviocytes as a Potential Source of Extracellular Survivin

Authors: Joong Kyong Ahn, Ji-Min Oh, Jaejoon Lee, Eun-Kyung Bae, Kwang-Sung Ahn, Hoon-Suk Cha, Eun-Mi Koh

Published in: Inflammation | Issue 6/2010

Login to get access

Abstract

Survivin belongs to the family of inhibitor of apoptosis proteins and plays an important role in the hyperplastic growth of tissues and tumors. In this study, we assessed the expression of survivin in rheumatoid synovial fluids (SF) and synovial tissues (ST) of rheumatoid arthritis (RA) patients in order to investigate the role of extracellular survivin in the pathogenesis of RA. The survivin level from SF was significantly higher in RA patients (n = 38) than in osteoarthritis patients (n = 18; 10.68 ± 2.76 vs. 1.0 ± 0.56 pg/ml, p = 0.02). In addition, SF survivin level was higher in erosive RA patients (n = 23) than in non-erosive RA patients (n = 15; 15.26 ± 4.26 vs. 4.47 ± 1.12 pg/ml, p = 0.05). SF survivin level in RA was positively correlated with disease activity score 28, but did not reach statistical significance (r = 0.309, p = 0.07). RA SF survivin level was also positively correlated with peripheral blood leukocyte counts (r = 0.443, p = 0.005). The immunohistochemical staining and Western blot analysis revealed survivin expression in the ST and fibroblast-like synoviocytes of RA patients, respectively. These findings suggest that extracellular survivin may be produced from rheumatoid FLS and may play an important role in the destructive RA process.
Literature
1.
go back to reference Bresnihan, B., P.P. Tak, P. Emery, L. Klareskog, and F. Breedveld. 2000. Synovial biopsy in arthritis research: five years of concerted European collaboration. Annals of the Rheumatic Diseases 59: 506–511.CrossRefPubMed Bresnihan, B., P.P. Tak, P. Emery, L. Klareskog, and F. Breedveld. 2000. Synovial biopsy in arthritis research: five years of concerted European collaboration. Annals of the Rheumatic Diseases 59: 506–511.CrossRefPubMed
2.
go back to reference Firestein, G.S. 1996. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis and Rheumatism 39: 1781–1790.CrossRefPubMed Firestein, G.S. 1996. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis and Rheumatism 39: 1781–1790.CrossRefPubMed
3.
go back to reference Baier, A., I. Meineckel, S. Gay, and T. Pap. 2003. Apoptosis in rheumatoid arthritis. Current Opinion in Rheumatology 15: 274–279.CrossRefPubMed Baier, A., I. Meineckel, S. Gay, and T. Pap. 2003. Apoptosis in rheumatoid arthritis. Current Opinion in Rheumatology 15: 274–279.CrossRefPubMed
4.
go back to reference Andersen, M.H., I.M. Svane, J.C. Becker, and P.T. Straten. 2007. The universal character of the tumor-associated antigen survivin. Clinical Cancer Research 13: 5991–5994.CrossRefPubMed Andersen, M.H., I.M. Svane, J.C. Becker, and P.T. Straten. 2007. The universal character of the tumor-associated antigen survivin. Clinical Cancer Research 13: 5991–5994.CrossRefPubMed
5.
go back to reference Li, F., and X. Ling. 2006. Survivin study: an update of "what is the next wave"? Journal of Cellular Physiology 208: 476–486.CrossRefPubMed Li, F., and X. Ling. 2006. Survivin study: an update of "what is the next wave"? Journal of Cellular Physiology 208: 476–486.CrossRefPubMed
6.
go back to reference Bokarewa, M., S. Lindblad, D. Bokarew, and A. Tarkowski. 2005. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther 7: R349–R358.CrossRefPubMed Bokarewa, M., S. Lindblad, D. Bokarew, and A. Tarkowski. 2005. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther 7: R349–R358.CrossRefPubMed
7.
go back to reference Mera, S., M. Magnusson, A. Tarkowski, and M. Bokarewa. 2008. Extracellular survivin up-regulates adhesion molecules on the surface of leukocytes changing their reactivity pattern. Journal of Leukocyte Biology 83: 149–155.CrossRefPubMed Mera, S., M. Magnusson, A. Tarkowski, and M. Bokarewa. 2008. Extracellular survivin up-regulates adhesion molecules on the surface of leukocytes changing their reactivity pattern. Journal of Leukocyte Biology 83: 149–155.CrossRefPubMed
8.
go back to reference Galeotti, L., K. Adrian, S. Berg, A. Tarkowski, and M. Bokarewa. 2008. Circulating survivin indicates severe course of juvenile idiopathic arthritis. Clinical and Experimental Rheumatology 26: 373–378.PubMed Galeotti, L., K. Adrian, S. Berg, A. Tarkowski, and M. Bokarewa. 2008. Circulating survivin indicates severe course of juvenile idiopathic arthritis. Clinical and Experimental Rheumatology 26: 373–378.PubMed
9.
go back to reference Park, M.C., S.J. Chung, Y.B. Park, and S.K. Lee. 2008. Relationship of angiogenic factors to disease activity and radiographic damage in rheumatoid arthritis. Clinical and Experimental Rheumatology 26: 881–886.PubMed Park, M.C., S.J. Chung, Y.B. Park, and S.K. Lee. 2008. Relationship of angiogenic factors to disease activity and radiographic damage in rheumatoid arthritis. Clinical and Experimental Rheumatology 26: 881–886.PubMed
10.
go back to reference Arnett, F.C., S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, M.H. Liang, H.S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 31: 315–324.CrossRefPubMed Arnett, F.C., S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, M.H. Liang, H.S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 31: 315–324.CrossRefPubMed
11.
go back to reference Ahn, J.K., H. Kim, J. Lee, E.K. Bae, H.S. Cha, and E.M. Koh. 2008. Phenotypic characterization and invasive properties of synovial fluid-derived adherent cells in rheumatoid arthritis. Inflammation 31: 365–371.CrossRefPubMed Ahn, J.K., H. Kim, J. Lee, E.K. Bae, H.S. Cha, and E.M. Koh. 2008. Phenotypic characterization and invasive properties of synovial fluid-derived adherent cells in rheumatoid arthritis. Inflammation 31: 365–371.CrossRefPubMed
12.
go back to reference Stebulis, J.A., R.G. Rossetti, F.J. Atez, and R.B. Zurier. 2005. Fibroblast-like synovial cells derived from synovial fluid. Journal of Rheumatology 32: 301–306.PubMed Stebulis, J.A., R.G. Rossetti, F.J. Atez, and R.B. Zurier. 2005. Fibroblast-like synovial cells derived from synovial fluid. Journal of Rheumatology 32: 301–306.PubMed
13.
go back to reference Deveraux, Q.L., and J.C. Reed. 1999. IAP family proteins—suppressors of apoptosis. Genes and Development 13: 239–252.CrossRefPubMed Deveraux, Q.L., and J.C. Reed. 1999. IAP family proteins—suppressors of apoptosis. Genes and Development 13: 239–252.CrossRefPubMed
14.
go back to reference Fortugno, P., N.R. Wall, A. Giodini, D.S. O'Connor, J. Plescia, K.M. Padgett, S. Tognin, P.C. Marchisio, and D.C. Altieri. 2002. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. Journal of Cell Science 115: 575–585.PubMed Fortugno, P., N.R. Wall, A. Giodini, D.S. O'Connor, J. Plescia, K.M. Padgett, S. Tognin, P.C. Marchisio, and D.C. Altieri. 2002. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. Journal of Cell Science 115: 575–585.PubMed
15.
go back to reference Khan, S., J.R. Aspe, M.G. Asumen, F. Almaguel, O. Odumosu, S. Acevedo-Martinez, M. De Leon, W.H. Langridge, and N.R. Wall. 2009. Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. British Journal of Cancer 100: 1073–1086.CrossRefPubMed Khan, S., J.R. Aspe, M.G. Asumen, F. Almaguel, O. Odumosu, S. Acevedo-Martinez, M. De Leon, W.H. Langridge, and N.R. Wall. 2009. Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. British Journal of Cancer 100: 1073–1086.CrossRefPubMed
16.
go back to reference Mita, A.C., M.M. Mita, S.T. Nawrocki, and F.J. Giles. 2008. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clinical Cancer Research 14: 5000–5005.CrossRefPubMed Mita, A.C., M.M. Mita, S.T. Nawrocki, and F.J. Giles. 2008. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clinical Cancer Research 14: 5000–5005.CrossRefPubMed
17.
go back to reference Altieri, D.C. 2003. Validating survivin as a cancer therapeutic target. Nature Reviews Cancer 3: 46–54.CrossRefPubMed Altieri, D.C. 2003. Validating survivin as a cancer therapeutic target. Nature Reviews Cancer 3: 46–54.CrossRefPubMed
18.
go back to reference Pope, R.M. 2002. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nature Reviews Immunology 2: 527–535.CrossRefPubMed Pope, R.M. 2002. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nature Reviews Immunology 2: 527–535.CrossRefPubMed
19.
go back to reference Baran, M., L.N. Mollers, S. Andersson, I.M. Jonsson, A.K. Ekwall, J. Bjersing, A. Tarkowski, and M. Bokarewa. 2009. Survivin is an essential mediator of arthritis interacting with urokinase signalling. J Cell Mol Med 13: 3797–3808.CrossRefPubMed Baran, M., L.N. Mollers, S. Andersson, I.M. Jonsson, A.K. Ekwall, J. Bjersing, A. Tarkowski, and M. Bokarewa. 2009. Survivin is an essential mediator of arthritis interacting with urokinase signalling. J Cell Mol Med 13: 3797–3808.CrossRefPubMed
20.
go back to reference Dharmapatni, A.A., M.D. Smith, D.M. Findlay, C.A. Holding, A. Evdokiou, M.J. Ahern, H. Weedon, P. Chen, G. Screaton, X.N. Xu, and D.R. Haynes. 2009. Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther 11: R13.PubMed Dharmapatni, A.A., M.D. Smith, D.M. Findlay, C.A. Holding, A. Evdokiou, M.J. Ahern, H. Weedon, P. Chen, G. Screaton, X.N. Xu, and D.R. Haynes. 2009. Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther 11: R13.PubMed
21.
go back to reference McInnes, I.B., and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews Immunology 7: 429–442.CrossRefPubMed McInnes, I.B., and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews Immunology 7: 429–442.CrossRefPubMed
22.
go back to reference Quehenberger, O. 2005. Thematic review series: the immune system and atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis. Journal of Lipid Research 46: 1582–1590.CrossRefPubMed Quehenberger, O. 2005. Thematic review series: the immune system and atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis. Journal of Lipid Research 46: 1582–1590.CrossRefPubMed
23.
go back to reference Tucker, G.C. 2006. Integrins: molecular targets in cancer therapy. Current Oncology Reports 8: 96–103.CrossRefPubMed Tucker, G.C. 2006. Integrins: molecular targets in cancer therapy. Current Oncology Reports 8: 96–103.CrossRefPubMed
24.
go back to reference Hanashi, M., T. Hayashi, and T. Saito. 2005. Expression of survivin in synovium and cartilage in DBA/1 J mice with type II collagen-induced arthritis. Clinical and Experimental Rheumatology 23: 550.PubMed Hanashi, M., T. Hayashi, and T. Saito. 2005. Expression of survivin in synovium and cartilage in DBA/1 J mice with type II collagen-induced arthritis. Clinical and Experimental Rheumatology 23: 550.PubMed
25.
go back to reference Ritchlin, C. 2000. Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Research 2: 356–360.CrossRefPubMed Ritchlin, C. 2000. Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Research 2: 356–360.CrossRefPubMed
26.
go back to reference Salmon, M., D. Scheel-Toellner, A.P. Huissoon, D. Pilling, N. Shamsadeen, H. Hyde, A.D. D'Angeac, P.A. Bacon, P. Emery, and A.N. Akbar. 1997. Inhibition of T cell apoptosis in the rheumatoid synovium. Journal of Clinical Investigation 99: 439–446.CrossRefPubMed Salmon, M., D. Scheel-Toellner, A.P. Huissoon, D. Pilling, N. Shamsadeen, H. Hyde, A.D. D'Angeac, P.A. Bacon, P. Emery, and A.N. Akbar. 1997. Inhibition of T cell apoptosis in the rheumatoid synovium. Journal of Clinical Investigation 99: 439–446.CrossRefPubMed
Metadata
Title
Increased Extracellular Survivin in the Synovial Fluid of Rheumatoid Arthritis Patients: Fibroblast-like Synoviocytes as a Potential Source of Extracellular Survivin
Authors
Joong Kyong Ahn
Ji-Min Oh
Jaejoon Lee
Eun-Kyung Bae
Kwang-Sung Ahn
Hoon-Suk Cha
Eun-Mi Koh
Publication date
01-12-2010
Publisher
Springer US
Published in
Inflammation / Issue 6/2010
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-010-9196-1

Other articles of this Issue 6/2010

Inflammation 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.